MINI FUTURE SHORT - BRISTOL-MYERS SQUIBB | Real-time Bid/Ask 12:53:43 17/06/2024 pm IST | ||
| 3.13 EUR / 3.16 EUR | +0.80% |
|
| Current month | -0.32% | ||
| 1 month | +12.64% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 15/24/15 | 3.12 | +0.97% |
| 13/24/13 | 3.09 | +4.04% |
| 12/24/12 | 2.97 | 0.00% |
| 11/24/11 | 2.97 | -1.66% |
| 10/24/10 | 3.02 | -2.58% |
Delayed Quote Börse Stuttgart
Last update June 15, 2024 at 12:49 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB979D |
| ISIN | DE000MB979D3 |
| Date issued | 27/07/2023 |
| Strike | 74.87 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.2 € |
|---|---|
| Lowest since issue | 1.08 € |
| Spread | 0.03 € |
| Spread % | 0.95% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2
USD
Average target price
53.19
USD
Spread / Average Target
+29.11%
- Stock Market
- Certificates
- Certificat
